Floatz logo

Ridaforolimus

Myeloid Metaplasia

Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myeloid Metaplasia cohort.

Asset / SponsorPhaseRating
Pomalidomide
Celgene
Phase 2B
PREDNISONE TABLETS
Celgene
Phase 2B
Tak-901
Millennium Pharmaceuticals, Inc.
Phase 1CC

Same molecule, other indications

Ridaforolimus is also rated in:

lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →